7.05
Schlusskurs vom Vortag:
$7.10
Offen:
$7.12
24-Stunden-Volumen:
378.85K
Relative Volume:
0.61
Marktkapitalisierung:
$380.55M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-4.462
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-10.08%
1M Leistung:
+0.79%
6M Leistung:
+72.37%
1J Leistung:
-18.02%
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
FULC
Fulcrum Therapeutics Inc
|
7.05 | 423.20M | 2.81M | -97.34M | -91.47M | -1.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2024-09-12 | Herabstufung | Stifel | Buy → Hold |
2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
2023-09-25 | Eingeleitet | Goldman | Neutral |
2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2023-08-22 | Hochstufung | Stifel | Hold → Buy |
2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-03-09 | Herabstufung | Stifel | Buy → Hold |
2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
2022-11-15 | Eingeleitet | Goldman | Buy |
2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
2021-03-02 | Eingeleitet | Stifel | Buy |
2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
2020-06-17 | Eingeleitet | BTIG Research | Buy |
2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
What drives Fulcrum Therapeutics Inc. stock priceOutstanding yields - Autocar Professional
What analysts say about Fulcrum Therapeutics Inc. stockOutstanding risk-reward balance - jammulinksnews.com
Fulcrum Therapeutics Inc. Stock Analysis and ForecastAccelerated earnings growth - jammulinksnews.com
Is Fulcrum Therapeutics Inc. a good long term investmentHigh-yield growth strategies - jammulinksnews.com
why fulcrum therapeutics inc. stock attracts strong analyst attentionWeekly Double Return List - Newser
What makes Fulcrum Therapeutics Inc. stock price move sharplyMarket Ready Callouts - Newser
Why Fulcrum Therapeutics Inc. stock attracts strong analyst attentionShort Term Risk Controlled Alerts - Newser
How Fulcrum Therapeutics Inc. stock performs during market volatilitySafe High Return Entry Points - Newser
Fulcrum Therapeutics (FULC) Drops 2.25% Despite 3.25% Intraday Gain - AInvest
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics Awards Major Stock Options Package Worth $912,600 to Strategic New Hire - Stock Titan
Fulcrum Therapeutics (FULC) Soars 14.31% on Earnings Report - AInvest
Fulcrum Therapeutics (NASDAQ:FULC) investors are sitting on a loss of 60% if they invested five years ago - Yahoo Finance
Fulcrum Therapeutics Elects New Directors at Annual Meeting - TipRanks
Is Fulcrum Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Cantor Fitzgerald Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC) - The Globe and Mail
Bank of America Corp DE Has $432,000 Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Research Analysts Issue Forecasts for FULC FY2026 Earnings - Defense World
Citadel Advisors LLC Makes New $69,000 Investment in Lisata Therapeutics, Inc. (NASDAQ:LSTA) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Millennium Management LLC - Defense World
Comparing Fulcrum Therapeutics (NASDAQ:FULC) and Lakeshore Biopharma (NASDAQ:LSB) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Two Sigma Investments LP - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Fulcrum Therapeutics Awards Major Stock Options Package: 70,000 Shares at $6.96 Exercise Price - Stock Titan
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory - MSN
BNP Paribas Financial Markets Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) shareholders are up 16% this past week, but still in the red over the last five years - simplywall.st
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):